Rodríguez-Gilabert C

Idioma: Inglés [English version]
Referencias bibliográficas: 11
Paginas: s209-211
Archivo PDF: 254.86 Kb.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Gencer B, Marston NA, Im K, Cannon CP, Sever P, Keech A et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020; 396 (10263): 1637-1643.

2. Mortensen MB, Nordestgaard BG. Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary prevention cohort. Lancet. 2020; 396 (10263): 1644-1652.

3. Ramos R, Comas-Cufí M, Martí-Lluch R, Balló E, Ponjoan A, Alves-Cabratosa L et al. Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study. BMJ. 2018; 362: k3359.

4. Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med. 2010; 152 (8): 488-96, W174.

5. Newman WP 3rd, Freedman DS, Voors AW, Gard PD, Srinivasan SR, Cresanta JL et al. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study. N Engl J Med. 1986; 314 (3): 138-144.

6. McMahan CA, Gidding SS, Malcom GT, Tracy RE, Strong JP, McGill HCJ. Pathobiological determinants of atherosclerosis in youth risk scores are associated with early and advanced atherosclerosis. Pediatrics. 2006; 118 (4): 1447-1455.

7. Steinberger J, Daniels SR, Hagberg N, Isasi CR, Kelly AS, Lloyd-Jones D et al. Cardiovascular health promotion in children: challenges and opportunities for 2020 and beyond: a scientific statement from the American Heart Association. Circulation. 2016; 134 (12): e236-255.

8. Klag MJ, Ford DE, Mead LA, He J, Whelton PK, Liang KY et al. Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med. 1993; 328 (5): 313-318.

9. Zeitouni M, Nanna MG, Sun JL, Chiswell K, Peterson ED, Navar AM. Performance of guideline recommendations for prevention of myocardial infarction in young adults. J Am Coll Cardiol. 2020; 76 (6): 653-664.

10. McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, hypertension, and obesity in youth committee, council of cardiovascular disease in the young, with the council on cardiovascular nursering. Circulation. 2007; 115 (14): 1948-1967.

11. Tonelli M, Wanner C. Lipid management in chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2013 clinical practice guideline. Ann Intern Med. 2014; 160 (3): 182.